About EDGAR Online | Login
 
The following is an excerpt from a 10-K SEC Filing, filed by DRUGSTORE COM INC on 3/18/2005.
Next Section Next Section Previous Section Previous Section
DRUGSTORE COM INC - 10-K - 20050318 - MARKET
ITEM 5.   MARKET FOR REGISTRANT’S COMMON STOCK AND RELATED SHAREHOLDER MATTERS

 

Market Information

 

Our common stock has been quoted on the Nasdaq National Market under the symbol “DSCM” since our initial public offering on July 27, 1999. Prior to that time, there was no public market for our common stock. The following table sets forth, for the periods indicated, the high and low sales prices of our common stock, as reported by the Nasdaq National Market.

 

     High

   Low

Fiscal Year Ended January 2, 2005

             

First Quarter

   $ 8.00    $ 4.76

Second Quarter

   $ 6.08    $ 2.89

Third Quarter

   $ 3.52    $ 2.02

Fourth Quarter

   $ 3.98    $ 2.91
     High

   Low

Fiscal Year Ended December 28, 2003

             

First Quarter

   $ 4.23    $ 1.99

Second Quarter

   $ 6.29    $ 3.33

Third Quarter

   $ 9.19    $ 4.53

Fourth Quarter

   $ 8.90    $ 4.90

 

Holders

 

On March 2, 2005, the last reported sale price of our common stock on the Nasdaq National Market was $2.15 per share. As of March 2, 2005, there were approximately 834 holders of record of our common stock, although there are a much larger number of beneficial owners.

 

Dividends

 

We have never declared or paid cash or stock dividends on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation and expansion of our business and do not anticipate paying any dividends in the foreseeable future.

 

Recent Sales of Unregistered Securities

 

On October 12, 2004, we entered into a settlement agreement and mutual release, dated as of October 7, 2004, with Arlington Contact Lens Service, Inc., or AC Lens, in connection with the settlement of a lawsuit relating to a commercial dispute between us and AC Lens. Under the terms of the settlement agreement, we issued 135,930 shares of our common stock to AC Lens. The issuance of these shares was exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, as a private offering under Section 4(2) of the Securities Act.

 

On February 14, 2005, in connection with the performance of services, we issued to Heidrick & Struggles, Inc. a warrant to purchase 125,000 shares of our common stock at $2.36 per share. The issuance of this warrant was exempt from registration under the Securities Act as a private offering under Section 4(2) of the Securities Act.

 

On March 2, 2005, we issued 10 million shares of our common stock to Ziff Asset Management, L.P. for an aggregate purchase price of $26.0 million in cash. The sale of these shares was exempt from registration under the Securities Act as a private offering to an “accredited investor” under Section 4(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act.

 

32


Table of Contents